Angina Pectoris Drugs Market To Reach $15.71 Billion By 2030

Angina Pectoris Drugs Market Growth & Trends

The global angina pectoris drugs market is expected to be valued at USD 15.71 billion by 2030, registering a CAGR of 4.0% from 2024 to 2030, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

 Request a free sample copy or view report summary: Angina Pectoris Drugs Market Report

Angina Pectoris Drugs Market Report Highlights

• The stable angina segment dominated the angina pectoris drug market with a revenue share of 52.2% in 2023. The number of patients suffering from chronic stable angina is rising, and almost half of these patients have it as the initial sign of ischemic heart disease.

• Beta blockers dominated the angina pectoris market in 2023 with a revenue share of 38.8%. Segment growth is primarily driven by its increasing adoption as a first-line therapy for angina pectoris.

• Hospital pharmacies dominate the angina pectoris drugs market with a revenue share of 48.5% in 2023. This can be attributed to the fact that hospitals equipped with advanced infrastructure and suitable facilities are witnessing a rise in the number of patients seeking treatment for angina pectoris disorders.

• North America angina pectoris drugs market dominated the global angina pectoris drugs market with a revenue share of over 40.0% in 2023. The increasing demand for minimally invasive procedures is expected to drive the market’s growth in the forecast period.

• Angina pectoris drugs market in Asia Pacific is expected the fastest growth in the global angina pectoris drugs market with a CAGR of 5.5%.

Angina Pectoris Drugs Market Segmentation

Grand View Research has segmented global angina pectoris drugs market report based on type, drug class, distribution channel, and region:

Angina Pectoris Drugs Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Stable Angina

• Unstable Angina

• Microvascular Angina

• Prinzmetal Angina

Angina Pectoris Drugs Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)

• Beta Blockers

• Calcium Antagonists

• Nitrates

• Anticoagulants

• Anti-Platelets

• Other Drug Classes

Angina Pectoris Drugs Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Angina Pectoris Drugs Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• Nort America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Angina Pectoris Drugs Market

• Pfizer Inc.

• Bayer AG

• AstraZeneca

• Gilead Sciences

• Novartis AG

• GlaxoSmithKline Plc.

• Merck & Co., Inc.

• Amgen Inc.

• Eli Lilly and Company

• Otsuka Pharmaceutical Co., Ltd.

• Sanofi S.A.

• Boehringer Ingelheim International GmbH